Endothelial activation by platelets from sickle cell anemia patients

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Proenca̧ Ferreira, Renata ^a   Brugnerotto, Ana Flav́ia ^a   Garrido, Vanessa Tonin ^a   Dominical, Venina Marcela ^a   Vital, Daiana Morelli ^a   Ribeiro, Marilenede Fat́ima Reis ^b   Santos, Melissa Ercolin Dos ^b   Traina, Fabíola ^a,c   Olalla Saad, Sara T ^a   Costa, Fernando Ferreira ^a   Conran, Nicola ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Children's Center for Hematologic Investigations Dr Domingos A Boldrini   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; PADGEM PROTEIN; THROMBOCYTE FACTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIGEN BINDING; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; ICAM GENE; IKKBETA GENE; MALE; NFKB1 GENE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SICKLE CELL ANEMIA; THROMBOCYTE ACTIVATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BLOOD PLATELETS; CELL ADHESION; COCULTURE TECHNIQUES; E-SELECTIN; FEMALE; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; INTERLEUKIN-8; MALE; MIDDLE AGED; NF-KAPPA B; NITRILES; P-SELECTIN; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SULFONES;

EID: 84895809710     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089012     Document Type: Article

References (43)

1. Stuart MJ, Nagel RL (2004) Sickle-cell disease. Lancet 364: 1343-1360. (Pubitemid 39335827)
2. Conran N, Franco-Penteado CF, Costa FF (2009) Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 33: 1-16.
3. Adams RJ (2007) Big strokes in small persons. Arch Neurol 64: 1567-1574.
4. Sparkenbaugh E, Pawlinski R (2013) Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol.
5. Noubouossie DC, Le PQ, Rozen L, Ziereisen F, Willems D, et al. (2013) Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial doppler velocity, and hydroxyurea treatment. Eur J Haematol.
6. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, et al. (1994) Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 71: 169-172. (Pubitemid 24047320)
7. Stuart MJ, Setty BN (2001) Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 20: 27-46. (Pubitemid 32168001)
8. Francis RB Jr (1989) Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 19: 105-111.
9. Setty BN, Key NS, Rao AK, Gayen-Betal S, Krishnan S, et al. (2012) Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol 157: 370-380.
10. Colella MP, De Paula EV, Conran N, Machado-Neto JA, Annicchino-Bizzacchi JM, et al. (2012) Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. J Thromb Haemost 10: 1967-1970.
11. Solovey A, Gui L, Key NS, Hebbel RP (1998) Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 101: 1899-1904. (Pubitemid 28226109)
12. Kenny MW, George AJ, Stuart J (1980) Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 33: 622-625. (Pubitemid 10036711)
13. Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, et al. (1998) Platelet activation in patients with sickle cell disease. Br J Haematol 100: 741-749. (Pubitemid 28126109)
14. Proenca-Ferreira R, Franco-Penteado CF, Traina F, Saad ST, Costa FF, et al. (2010) Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. Br J Haematol 149: 280-288.
15. Triadou P, Fonty E, Ambrosio AS, Cottat MC, Girot R, et al. (1990) Platelet function in sickle cell disease during steady state. Nouv Rev Fr Hematol 32: 137-142. (Pubitemid 20163244)
16. Mehta P, Mehta J (1980) Abnormalities of platelet aggregation in sickle cell disease. J Pediatr 96: 209-213. (Pubitemid 10129398)
17. Tomer A (2004) Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 18: 172-177.
18. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV (2006) Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 26: 1626-1631. (Pubitemid 44288993)
19. Garrido VT, Proenca-Ferreira R, Dominical VM, Traina F, Bezerra MA, et al. (2012) Elevated plasma levels and platelet-associated expression of the prothrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease. Br J Haematol 158: 788-797.
20. Browne PV, Mosher DF, Steinberg MH, Hebbel RP (1996) Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 51: 296-301. (Pubitemid 26116369)
21. Novelli EM, Kato GJ, Ragni MV, Zhang Y, Hildesheim ME, et al. (2012) Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am J Hematol 87: 326-330.
22. Tomer A, Harker LA, Kasey S, Eckman JR (2001) Thrombogenesis in sickle cell disease. J Lab Clin Med 137: 398-407. (Pubitemid 32473618)
23. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, et al. (1997) Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 129: 507-516. (Pubitemid 27285047)
24. Setty BN, Rao AK, Stuart MJ (2001) Thrombophilia in sickle cell disease: the red cell connection. Blood 98: 3228-3233.
25. Setty BN, Kulkarni S, Rao AK, Stuart MJ (2000) Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood 96: 1119-1124. (Pubitemid 30616882)
26. Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, et al. (2010) P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol 30: 2392-2399.
27. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T (2002) Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 24: 81-88. (Pubitemid 35013546)
28. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, et al. (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110: 2166-2172. (Pubitemid 47443936)
29. Sakamoto TM, Canalli AA, Traina F, Franco-Penteado CF, Gambero S, et al. (2013) Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. Clin Biochem.
30. Finco TS, Baldwin AS (1995) Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity 3: 263-272.
31. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071. (Pubitemid 27163860)
32. Epinat JC, Gilmore TD (1999) Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 18: 6896-6909.
33. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, et al. (2009) Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 15: 384-391.
34. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, et al. (2013) Activated platelets can deliver mRNA regulatory Ago2.microRNA complexes to endothelial cells via microparticles. Blood 122: 253-261.
35. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM (2000) Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 96: 2451-2459.
36. Charneski L, Congdon HB (2010) Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature. Am J Health Syst Pharm 67: 895-900.
37. Osamo NO, Photiades DP, Famodu AA (1981) Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 66: 102-107. (Pubitemid 11041813)
38. Chaplin H Jr, Monroe MC, Malecek AC, Morgan LK, Michael J, et al. (1989) Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J 66: 574-584.
39. Chaplin H Jr, Alkjaersig N, Fletcher AP, Michael JM, Joist JH (1980) Aspirindipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost 43: 218-221. (Pubitemid 10044802)
40. Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, et al. (2013) A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 6: 17.
41. Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, et al. (2013) A Phase 1 Study of Prasugrel in Patients with Sickle Cell Disease: Pharmacokinetics and Effects on ex Vivo Platelet Reactivity. Br J Clin Pharmacol 75:1433-1444.
42. Lee SP, Ataga KI, Zayed M, Manganello JM, Orringer EP, et al. (2007) Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol 139: 612-620. (Pubitemid 350043807)
43. Desai PC, Brittain JE, Jones SK, McDonald A, Wilson DR, et al. (2013) A Pilot Study of Eptifibatide for Treatment of Acute Pain Episodes in Sickle Cell Disease. Thromb Res 132:341-345.